

KARI REMES

LIST OF PUBLICATIONS

A) ORIGINAL SCIENTIFIC ARTICLES

16. Tienhaara A, Remes K, Pelliniemi T-T: Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma. *Br J Haemat* 77:335-338, 1991
DOI: 10.1111/j.1365-2141.1991.tb08580.x
17. Finnish Leukaemia Group: Palva IP, Almqvist A, Elonen E, Hänninen A, Jouppila J, Järventie G, Koivunen E, Kätkä K, Lahtinen R, Oivanen T, Pelliniemi TT, Rajamäki A, Remes K, Ruutu T, Timonen T, Wasastjerna C, Vilpo J, Volin L, Vuopio P: Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia. *Eur J Haematol* 47:229-233, 1991
DOI: 10.1111/j.1600-0609.1991.tb01560.x
18. Remes K, Tienhaara A, Pelliniemi T-T: Priming therapy with alpha-interferon in chemotherapy-resistant multiple myeloma. *Leuk Lymphoma* 6:239-243, 1992
<http://dx.doi.org/10.3109/10428199209064901>
19. Finnish Leukaemia Group (Palva I P, Ahrenberg P, Ala-Harja K, Almqvist A, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Jouppila J, Järvenpää E, Järventie G, Kilpi H, Koivunen E, Kätkä K, Kääriäinen M, Lahtinen R, Laitinen A, Lehtinen M, Mäkelä H, Nyländen P, Oivanen T, Pelliniemi T-T, Pulli T, Rajamäki A, Remes K, Rosengård S, Soininen K, Timonen T, Wasastjerna C, Vilpo J): Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. *Eur J Haematol* 48:37-40, 1992
DOI: 10.1111/j.1600-0609.1992.tb01791.x
20. Itälä M, Helenius H, Nikoskelainen J, Remes K: Infections and serum IgG levels in patients with chronic lymphocytic leukemia. *Eur J Haematol*. 48:266-270, 1992
DOI: 10.1111/j.1600-0609.1992.tb01805.x
21. Paul R, Remes K: The disposable teaspoon - a lethal risk to neutropenic patients (Letter to the editor). *Eur J Haematol* 50:125, 1993
DOI: 10.1111/j.1600-0609.1993.tb00154.x
22. Koskela K, Pelliniemi T-T, Remes K: VAD regimen in the

treatment of resistant multiple myeloma: slow or fast infusion? *Leuk Lymphoma* 10:347-351, 1993
DOI: 10.1111/j.1600-0609.1993.tb00154.x

23. Remes K, Pelliniemi T-T: Alfainterferonihoito kroonisiin myeloproliferatiivisiin tauteihin liittyvässä trombosytoosissa. *Duodecim* 109:983-989, 1993
(Treatment with alfa-interferon of thrombocytosis in chronic myeloproliferative diseases)
<http://www.duodecimlehti.fi/lehti/1993/11/duo30174>
24. Remes K, Tienhaara A, Pelliniemi T-T: Alpha interferon raises serum beta-2-microglobulin in patients treated for thrombocythaemia. *Br J Haematol* 84:353-355, 1993
25. Hovi I, Taavitsainen M, Lantto T, Vorne M, Paul R, Remes K: Technetium-99m-HMPAO-labeled leukocytes and technetium-99m-labeled human polyclonal immunoglobulin G in diagnosis of focal purulent disease. *J Nucl Med* 9:1428-1434, 1993
<http://jnm.snmjournals.org/content/34/9/1428.long>
26. Finnish Leukaemia Group: Palva IP, Ala-Harja K, Almqvist A, Elonen E, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Joupila J, Järvenpää E, Järventie G, Kilpi H, Koistinen P, Koivunen E, Kätkä K, Kääriäinen M, Lahtinen R, Laitinen A, Lehtinen M, Mäkelä H, Nyländen P, Nyman D, Oivanen T, Pelliniemi T-T, Pulli T, Rajamäki A, Remes K, Rosengård S, Ruutu T, Soinen K, Timonen T, Wasastjerna C, Vilpo J, Volin L: Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. *Eur J Haematol* 51:98-101, 1993
DOI: 10.1111/j.1600-0609.1993.tb01600.x
27. Remes K, Paul R, Pelliniemi T-T: Interferon does not prevent leukemic evolution in patients with multiple myeloma. *Leukemia* 7:1072-1073, 1993
PMID: 8321024
28. Paul R, Remes K: Kun kertakäyttölusikka on viedä ihmishengen. *Duodecim* 109:2158-2160, 1993
29. Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M, Nousiainen T, Pelliniemi T-T, Rajamäki A, Remes K, Sarkkinen R, Sinisalo M, Timonen T, Volin L and Elonen E for the Finnish Leukaemia Group: Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients. *Leukemia* 8:11-15, 1994
PMID: 8289475
30. Paul R, Remes K, Lakkala T, Pelliniemi TT: Spontaneous

remission in AML. Br J Haemat 86:210-212, 1994
DOI: 10.1111/j.1365-2141.1994.tb03281.x

31. Remes K, Paul R ja Vanhatalo S: Granulosyyttikasvutekijät - kokemuksia veritautipotilaiden hoidossa. Suom Lääklehti 28: 2757-2763, 1994
(Granulocyte growth factors - experiences in treatment of haematological patients)
32. Björkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, Prentice HG, Cavo M, Samson D, de Laurenzi A, Verdonck LF, Proctor S, Ferrant A, Sierra J, Auzanneau G, Troussard X, Gravett P, Remes K, Gahrton G: Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT registry study. Leuk Lymphoma 15:265-272, 1994
DOI: 10.1038/sj.bmt.1702826
33. Tertti R, Alanen A, Remes K: The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 91:658-660, 1995
DOI: 10.1111/j.1365-2141.1995.tb05363.x
34. Björkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, Auzanneau G, Blade J, Brunet S, Carlson K, Cavo M, Ferrant A, Gravett P, de Laurenzi A, Prentice HG, Proctor S, Remes K, Troussard X, Verdonck LF, Williams C, Gahrton G: Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 13 (Suppl.2):140-146, 1995
DOI: 10.1002/stem.5530130722
35. Pulkki K, Neva M, Koskela K, Ollikainen H, Remes K, Pelliniemi T-T: Il-6-mediated growth inhibition by all-trans-retinoic acid but not by alpha-interferon in human myeloma cells. Annals NY Acad Sci 762:457-458, 1995
DOI: 10.1111/j.1749-6632.1995.tb32366.x
36. Remes K, Tienhaara A, Pelliniemi T-T: Effects of alpha-interferon on serum beta-2-microglobulin. Leuk Lymph 21:233-238, 1996
DOI: 10.3109/10428199209067605
37. Itälä M, Remes K: The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukemia. Leuk Lymph 23:137-141, 1996
DOI: 10.3109/10428199609054812
38. Itälä M, Vainio O, Remes K: Functional abnormalities in granulocytes predict susceptibility to bacterial infections

in chronic lymphocytic leukemia. Eur J Haematol 57:46-53, 1996

DOI: 10.1111/j.1600-0609.1996.tb00489.x

39. Itälä M, Pelliniemi T-T, Remes K: GM-CSF raises serum levels of beta-2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia. Br J Haematol 94:129-132, 1996
DOI: 10.1046/j.1365-2141.1996.6172066.x
40. Johnsen HE, Björkstrand B, Carlson K, Gruber A, Blystad A, Fast A, Boesen AM, Björkholm M, Sallerfors B, Ruutu T, Carneskog J, Malm A, Geisler C, Lehtinen M, Schröder H, Brinch L, **Remes K**, Tidefelt U, Heilmann C, Hörnsten P, Thorling K, Daugaard G: Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. Leuk Lymphoma 24: 81-91, 1996
DOI: 10.3109/10428199609045716
41. Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG, **Remes K**, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - a retrospective case-matched study from the European Group for Blood and Marrow Transplantation (EBMT). Blood 88: 4711-4718, 1996
PMID: 8977265
42. Remes K, Matinlauri I, Grenman S, Itälä M, Kauppila M, Pelliniemi T-T, Salminen E, Vanharanta-Hiltunen R, Rajamäki A: Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and post-transplant hematopoietic recovery. J Hematother 6:13-19, 1997
DOI: 10.1089/scd.1.1997.6.13
43. Ruutu T, Hänninen A, Järventie G, Koistinen P, Koivunen E, Kätkä K, Nousiainen T, Oksanen K, Pelliniemi T-T, Remes K, Timonen T, Volin L, Elonen E for the Finnish Leukemia Group: Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leukemia Res 21:133-138, 1997
[https://doi.org/10.1016/S0145-2126\(96\)00116-6](https://doi.org/10.1016/S0145-2126(96)00116-6)
44. Itälä M, Vanhatalo S, Remes K: Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: a crossover study. Leuk

Lymphoma 25:503-508, 1997
DOI: 10.3109/10428199709039038

45. Koskela K, Pelliniemi T-T, Remes K, Rajamäki A, Pulkki K: Serum oncostatin M in multiple myeloma: association with prognostic factors. *Br J Haematol* 96:158-160, 1997
PMID: 9012701

46. Itälä M, Kotilainen P, Nikkari S, Remes K, Nikoskelainen J: Pure red cell aplasia caused by B19 parvovirus infection after autologous blood stem cell transplantation in a patient with chronic lymphocytic leukemia. *Leukemia* 11:171, 1997
PMID: 9001436

47. Remes K, Rajamäki A, Grenman S, Itälä M, Kauppila M, Nikoskelainen J, Pelliniemi T-T, Ristamäki R, Salmi TT, Salmi T, Salminen E, Vanharanta R, Toivanen A: Luuytimensiirrosta veren kantasolujen siirtoon - kokemukset sadan ensimmäisen potilaan autologisesta kantasolujen siirrosta Turussa. *Duodecim* 113:219-228, 1997

48. Grenman S, Tholander B, Remes K, Kauppila M, Rajamäki A, Pelliniemi T-T, Rantanen V, Salmi TT, Carlsson K, Höglund M, Öberg G, Simonson B, Salmi T: High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer - initial experience in Uppsala and Turku. *Acta Obstet Gynecol Scand* 76:363-368, 1997
DOI: 10.1111/j.1600-0412.1997.tb07994.x

49. Itälä M, Pelliniemi T-T, Rajamäki A, Remes K: Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. *Bone Marrow Transplantation* 19:647-651, 1997
DOI: 10.1038/sj.bmt.1700730

50. Rintala E, Remes K, Salmi T T, Koskinen P, Nikoskelainen J: The effects of pretransplant conditioning, graft-versus-host disease and sepsis on the CRP levels in bone marrow transplantation. *Infection* 25 (6):335-338, 1997
PMID: 9427050

51. Kauppila M, Koskinen P, Remes K, Viikari J, Irjala K. Hypothalamic-pituitary axis remains intact after interferon- α treatment in hematologic diseases. *J Interferon Cytokine Res* 17:543-550, 1997
DOI: 10.1089/jir.1997.17.543

52. Itälä M, Pelliniemi T-T, Remes K, Vanhatalo S, Vainio O: Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections. *Leuk Lymphoma* 32:165-174, 1998
DOI: 10.3109/10428199809059257
53. Koskela K, Pelliniemi T-T, Lakkala T, Remes K. Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma. *Bone Marrow Transplantation* 21:305-307, 1998
DOI: 10.1038/sj.bmt.1701080
54. Elonen E, Almqvist A, Hänninen A, Jansson S-E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M, Nousiainen T, Pelliniemi T-T, Rajamäki A, **Remes K**, Timonen T, Vilpo J, Volin L, Ruutu T for the Finnish Leukemia Group. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. *Leukemia* 12:1041-1048, 1998
PMID: 9665188
55. Kauppila M, Koskinen P, Irjala K, Remes K, Viikari J. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults. *Bone Marrow Transplantation* 22:331-337, 1998
DOI: 10.1038/sj.bmt.1701337
56. Kauppila M, Viikari J, Irjala K, Koskinen P, Remes K. The hypothalamus-pituitary-gonad axis and testicular function in male patients after treatment for haematological malignancies. *J Intern Med* 244:411-416, 1998
DOI: 10.1046/j.1365-2796.1998.00390.x
57. Remes K, Rönnemaa T. Healing of chronic leg ulcers in diabetic necrobiosis lipoidica with local granulocyte-macrophage colony-stimulating factor treatment. *J Diabetes Complications* 13:115-118, 1999
[https://doi.org/10.1016/S1056-8727\(98\)00025-7](https://doi.org/10.1016/S1056-8727(98)00025-7)
58. Finnish Leukaemia Group (Oivanen T, Ala-Harja K, Almqvist A, Apajalahti J, Elonen E, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Jouppila J, Järvenpää E, Järventie G, Kilpi H, Koistinen P, Koistinen S, Koivisto A-M, Koivunen E, Korpi E, Kätkä K, Kääriäinen M, Lahtinen R, Laitinen A, Lehtinen M, Mäkelä H, Nyländen P, Nyman D, Palva I, Pelliniemi T-T, Pulli T, Rajamäki A, Rauhala A, **Remes K**, Rosengård S, Ruutu T, Soininen K, Tiilikainen J, Timonen T, Waris E, Vilpo J, Volin L. Long-term survival in multiple myeloma: a Finnish Leukaemia Group study. *Br J Haematol* 105:942-947, 1999
DOI: 10.1046/j.1365-2141.1999.01462.x

59. Kosme K, Remes K. AIHA - moni-ilmeinen anemia. Suomen Lääkl 54:2889-2895, 1999
(A review of AIHA)
60. Grenman S, Remes K, Inki P, Itälä M, Kauppila M, Pelliniemi T-T, Rajamäki A, Rantanen V, Salmi T T, Vuento M, Salmi T. Kokemukset 10 ensimmäisen munasarjasyöpöpotilaan suuriannoksisesta solunsalpaajahoidosta Turussa. Suomen Lääkl 28: 3359-3364, 1999
(Experiences of high dose therapy for the ten first patients with ovarian cancer in Turku)
61. Kauppila M, Irjala K, Koskinen P, Pulkki K, Sonninen P, Viikari J, Remes K. Bone mineral density after allogeneic bone marrow transplantation. Bone Marrow Transplant 24:885-889, 1999
DOI: 10.1038/sj.bmt.1701989
62. Järveläinen H, Remes K, Viikari J. Keski-ikäisen miehen vaikea osteoporoosi. Duodecim 115:2473-2476, 1999
(Severe osteoporosis of a middle-age man; case report)
63. Kauppila M, Koskinen P, Pulkki K, Sonninen P, Remes K, Irjala K, Viikari J. Interferon- α treatment decreases serum cross-linked C-terminal telopeptide of type I collagen in haematological diseases. Clin Lab Haematol 22:15-20, 2000
DOI: 10.1046/j.1365-2257.2000.00269.x
64. Michallet M, Thiebaur A, Dreger P, **Remes K**, Milpied N, Santini G, Hamon M, Björkstrand B, Kimby E, Belhabri A, Tanguy ML, Apperley JF. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 108: 595-601, 2000
DOI: 10.1046/j.1365-2141.2000.01900.x
65. Koskela K, Pelliniemi T-T, Rajamäki A, Pulkki K, **Remes K**. Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. Eur J Haematol 65: 52-56, 2000
DOI: 10.1034/j.1600-0609.2000.90167.x
66. The Finnish Leukaemia Group (Oivanen T, Ala-Harja K, Almqvist A, Apajalahti J, Elonen E, Hallman H, Hänninen A, Iivonen M, Isomaa B, Jouppila J, Järvenpää E, Järventie G, Kilpi H, Koistinen P, Koistinen S, Koivisto A-M, Koivunen E, Korpi E, Kätkä K, Kääriäinen M, Lahtinen R, Laitinen A, Lehtinen M, Mäkelä H, Nyländén P, Nyman D, Palva I, Pelliniemi T-T, Pulli T, Rajamäki A, Rauhala A, **Remes K**, Rosengård S, Ruutu

T, Soininen K, Tiilikainen J, Timonen T, Waris E, Vilpo J, Volin L). Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. *Eur J Haematol* 65: 123-127, 2000

DOI: 10.1034/j.1600-0609.2000.90218.x

67. Remes K, Paavonen T. Kuumeilu ja seerumin suuri laktaattidehydrogenaasipitoisuus luuytimensiirron jälkeen (kliinisch-patologinen kokousselostus). *Duodecim* 116: 1386-1393, 2000
(Fever and high LDH concentration after bone marrow transplantation; clinicopathological conference)
68. Itälä M, Remes K. Nukleosidianalogit - uusia lääkkeitä lymfaattisten syöpien hoitoon. *Duodecim* 117: 162-169, 2001
(Nucleoside analogues - new agents for treatment of lymphatic cancers)
69. Lammintausta K, Mäkelä L, Remes K. Lääkkeen aiheuttama säärihaava. *Duodecim* 117:31-33, 2001
(Drug-induced ulcerus cruris; case report)
70. Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, **Remes K**, Cornelissen JJ, Blade J, Lenhoff S, Iriando A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant* 27:511-515, 2001
DOI: 10.1038/sj.bmt.1702826
71. Koskela K, Pelliniemi TT, Pelliniemi LJ, **Remes K**, Söderström KO, Punnonen K, Kumar R, Ollikainen H, Pulkki K. Autocrine production and synergistic growth-promoting activity of interleukin 6 and oncostatin M in a new human myeloma cell line TU-1. *Acta Haematol* 107:23-28, 2002
PMID: 11818668
72. Vuento MH, Salmi TA, Remes KJ, Grenman SE. Hematological toxicity of salvage treatment after high-dose chemotherapy and conventional chemotherapy of ovarian cancer. *Anticancer Res* 22:1151-1155, 2002
PMID: 12168916
73. Ruutu T, Eriksson B, **Remes K**, Juvonen E, Volin L, Remberger M, Parkkali T, Hägglund H, Ringden O for the Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. *Blood* 100:1977-83, 2002

DOI: 10.1182/blood-2001-12-0159

74. Itälä M, Geisler CH, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, **Remes K**. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. *Eur J Haematol* 69:129-134, 2002
DOI: 10.1034/j.1600-0609.2002.02786.x
75. Remes K, Itälä M, Kauppila M, Pelliniemi T-T, Rajamäki A. Autologous blood cell transplantation in multiple myeloma: impact of CD34+ cell selection with long follow-up. *J Hematother Stem Cell Res* 12:63-70, 2003
DOI: 10.1089/152581603321210145
76. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahlamäki E, **Remes K**. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. *Bone Marrow Transplant* 31:347-351, 2003
DOI: 10.1038/sj.bmt.1703840
77. Björkstrand B, Rasmussen T, **Remes K**, Gruber A, Pelliniemi T-T, Johnsen HE. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study. *Eur J Haematol* 70:379-383, 2003
DOI: 10.1034/j.1600-0609.2003.00068.x
78. Itälä M, Remes K. Excellent response of refractory life-threatening thrombotic thrombocytopenic purpura to cyclosporine treatment. *Clin Lab Haematol* 26:65-67, 2004
DOI: 10.1046/j.0141-9854.2003.00573.x
79. Ruutu T, Koivunen E, Nousiainen T, Pelliniemi T-T, Almqvist A, Anttila P, Jantunen E, Koistinen P, Koponen A, Mikkola M, Oksanen K, Pulli T, **Remes K**, Sarkkinen R, Silvennoinen R, Timonen T, Vanhatalo S, Elonen E for the Finnish Leukaemia Group. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin and thioguanine in the second and third treatment cycle. *Eur J Haematol* 72:38-44, 2004
DOI: 10.1046/j.0902-4441.2003.00182.x
80. Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, Franssila K, Söderström KO, Leppä S, Elonen E, **Remes K**, Nousiainen T. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nationwide survey. *Bone Marrow Transplant* 33:405-410, 2004
DOI: 10.1038/sj.bmt.1704367
81. Koskela K, Pelliniemi TT, Pulkki K, **Remes K**. Treatment of

multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial. *Leuk Lymphoma* 45:749-754, 2004
DOI: 10.1080/10428190310001628158

82. Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T, Kuittinen O, Leppä S, Anttila V-A, Itälä M, Wiklund T, **Remes K**, Nousiainen T. Invasive fungal infections in autologous stem cell transplant recipients : a nation-wide study of 1188 transplanted patients. *Eur J Haematol* 73: 174-178, 2004
DOI: 10.1111/j.1600-0609.2004.00273.x

83. Itälä M, Aho H, **Remes K**. Reduced-intensity conditioning and blood stem cell transplantation from an HLA-identical sibling for severe aplastic anaemia: two patients with successful engraftment but a fatal post-transplant lymphoproliferative disorder in the other. *The Hematology J* 5: 440-443, 2004
DOI: 10.1038/sj.thj.6200381

84. Putkonen M, Rauhala A, Itälä M, Kauppila M, Pelliniemi T-T, **Remes K**. Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients. *Haematologica/Hematology J* 90:562-3, 2005
PMID: 15820960

85. Laaksonen S, **Remes K**, Koskela K, Voipio-Pulkki L-M, Falck B. Thalidomide therapy and polyneuropathy in myeloma patients. *Electromyogr. clin. Neurophysiol.* 45: 75-86, 2005
PMID: 15861857

86. Kuittinen T, Wiklund T, **Remes K**, Elonen E, Lehtinen T, Kuittinen O, Leppä S, Putkonen M, Rätty R, Turpeenniemi-Hujanen T, Nousiainen T, Jantunen E. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. *Eur J Haematol* 75: 199-205, 2005
DOI: 10.1111/j.1600-0609.2005.00481.x

87. **Remes K**, Luoma S, Salmi TT, Pelliniemi T-T, Itälä M, Kauppila M, Lähteenmäki P, Nikoskelainen J, Putkonen M, Kairisto V, Rajamäki A, Tienhaara A, Pyrhönen S, Rauhala A. Allogeenisten kantasolujensiirtojen kehityssuunnat ja niiden heijastuminen Turun siirtokeskuksen toimintaan ja tuloksiin. *Duodecim* 2005; 121: 2085-97.
(Trends in allogeneic stem cell transplantations and their impact on activities and results of the Turku Stem Cell Transplant Center)

88. Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E,

Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, **Remes K**, Volin L. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. *Eur J Haematol* 2006; 76: 245-250.

DOI: 10.1111/j.1600-0609.2005.00605.x

89. Jantunen E, Itälä M, Juvonen E, Leppä S, Keskinen L, Vasala K, **Remes K**, Wiklund T, Elonen E, Nousiainen T. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. *Bone Marrow Transplant* 2006; 37: 367-372

DOI: 10.1038/sj.bmt.1705266

90. Jantunen E, Itälä M, Siitonen T, Juvonen E, Koivunen E, Koistinen P, Volin L, **Remes K**, Nousiainen T. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. *Bone Marrow Transplant* 2006; 37: 1093-1098

DOI: 10.1038/sj.bmt.1705375

91. Jantunen E, Itälä M, Siitonen T, Koivunen E, Leppä S, Juvonen E, Kuittinen O, Lehtinen T, Koistinen P, Nyman H, Nousiainen T, Volin L, **Remes K**. Late non-relapse mortality among adult autologous stem cell transplant recipients : a nation-wide analysis of 1482 patients transplanted in 1990-2003. *Eur J Haematol* 2006; 77: 114-119

DOI: 10.1111/j.1600-0609.2006.00685.x

92. Koistinen P, Rätty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi T-T, **Remes K**, Ruutu T, Savolainen E-R, Siitonen T, Silvennoinen R, Volin L, Elonen E for the Finnish Leukemia Group. Long-term outcome of intensive chemotherapy for adults with *de novo* acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. *Eur H Haematol* 2007; 78:477-486.

DOI: 10.1111/j.1600-0609.2007.00846.x

93. Putkonen M, Rauhala A, Pelliniemi T-T, **Remes K**. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilisation failure in patients with multiple myeloma. *Cytotherapy* 2007; 9:548-554.

DOI: 10.1080/14653240701508429

94. Jantunen E, Itälä M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, Juvonen E, Silvennoinen R, Nousiainen T, Koistinen P, Volin L, **Remes K**. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. *Bone Marrow Transplant*. 2008;41:239-244.

DOI: 10.1038/sj.bmt.1705897

95. Hämäläinen MA, Kairisto V, Juvonen V, Johansson J, Auren J, Kohonen K, **Remes K**, Salmi TT, Helenius H, Pelliniemi T-T. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. *Eur J Haematol* 2008; 80:201-207
DOI: 10.1111/j.1600-0609.2007.01009.x
96. Itälä M, Huhtinen A-R, Juvonen V, Kairisto V, Pelliniemi T-T, Penttilä T-L, Rauhala A, Tienhaara A, **Remes K**. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of posttransplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR. *Eur J haematol* 2008; 81:100-6.
DOI: 10.1111/j.1600-0609.2008.01082.x
97. Putkonen M, Rauhala A, Pelliniemi T-T, Remes K. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. *Ann Hematol* 2009;88:673-80.
DOI: 10.1007/s00277-008-0675-5
98. Björkstrand B, Klausen TW, **Remes K**, Gruber A, Knudsen LM, Bergmann OJ, Lenhoff S, Johnsen HE. Double versus single high-dose melphalan 200 mg/m² and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area. *Hematology Reviews* 2009; vol 1:e2; 9-13
doi: 10.4081/hr.2009.e2
99. Johnsen HE, Boegsted M, Klausen TW, Gimsing P, Schmitz A, Kjaersgaard E, Damgaard T, Voss P, Knudsen LM, Mylin AK, Nielsen JL, Björkstrand B, Gruber A, Lenhoff S, **Remes K**, Dahl IM, Fogd K, Dybkaer K; Nordic Myeloma Study Group (NMSG); Myeloma Stem Cell Network (MSCNET). Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. *Cytometry B Clin Cytom* 2010; 78:338-347
DOI: 10.1002/cyto.b.20523
100. Airas L, Päivärinta M, Röyttä M, Karhu J, Kauppila M, Itälä-Remes M, **Remes K**. Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT. *Bone Marrow Transplant* 2010;45:593-6
DOI: 10.1038/bmt.2009.186
101. Syrjälä H, Ohtonen P, Kinnunen U, Rätty R, Elonen E, Nousiainen T, Jantunen E, **Remes K**, Itälä-Remes M, Silvennoinen R, Koistinen P; Finnish Leukemia Group. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. *Eur J Clin Microbiol Infect Dis* 2010;29:1211-8

DOI: 10.1007/s10096-010-0984-1

102. Hämäläinen M, Juvonen V, Häikiö S, Lakkala T, Johansson J, J, Pelliniemi T-T, Salmi TT, **Remes K**, Kairisto V. ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status. Eur J Haematol 2010;85:361-2

DOI: 10.1111/j.1600-0609.2010.01483.x

103. Putkonen M, Kairisto V, Juvonen V, Pelliniemi TT, Rauhala A, Itälä-Remes M, **Remes K**. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010; 85:416-23.

DOI: 10.1111/j.1600-0609.2010.01510.x

104. Johnsen HE, Geisler C, Juvonen E, **Remes K**, Juliusson G, Hörnsten P, Kvaloy S, Kvalheim G, Jurgensen GW, Pedersen LM, Bergmann OJ, Schmitz A, Boegsted M. Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment. Bone Marrow Transplant 2011;46:44-51

DOI: 10.1038/bmt.2010.84

105. Simonsson B, Gedde-Dahl T, Markevärn B, **Remes K**, Stentoft J Almqvist A, Björemann M, Flögegård M, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Räsänen A, Sinisalo M, Sjölander A, Strömberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A Nielsen JL, Hjorth-Hansen H, Porkka K; Nordic CML Study Group. Combination of pegylated IFN- α 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011;118: 3228-35.

DOI: 10.1182/blood-2011-02-336685

106. Toivari A, Itälä-Remes M, Kauppila M, Putkonen M, Salminen U, **Remes K**. Allogeeninen kantasolusiirto myelofibroosin hoidossa. Duodecim 2011;127:2375-82

107. Gruber FX, Lundan T, Goll R, Silye A, Mikkola I, Rekvig OP, Knuutila S, **Remes K**, Gedde-Dahl T, Porkka K, Hjorth-Hansen H. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogenous than just ABL kinase domain point mutations? Med Oncol 2012;29:219-26

DOI: 10.1007/s12032-010-9781-z

xxxxx

108. Abellsson J, Merup M, Birgegård G, Weisbjerrum O, Brinch L, Brune M, Johansson P, Kauppila M, Lenhoff S, Liljeholm M, Malm C, **Remes K**, Vindelöv

L, Andreasson B; Nordic MPD Study Group. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. *Bone Marrow Transplant* 2012;47:380-6
DOI: 10.1038/bmt.2011.91

109. Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, **Remes K**, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol* 2012;30:2211-17.
DOI: 10.1200/JCO.2011.37.4108
110. Salmenniemi U, Remes K. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. *Hematol Rep* 2012;4:e13.
DOI: 10.4081/hr.2012.e13
111. Virtanen JM, **Remes KJ**, Itälä-Remes MA, Saunavaara JP, Komu ME, Partanen AM, Parkkola RK. The relationship between cardiac and liver iron evaluated by IMR imaging in haematological malignancies and chronic liver disease. *Blood Cancer J* 2012 Jan;2:e49.
DOI: 10.1038/bcj.2011.48
112. Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundan T, Juvonen V, Luukkaala T, **Remes K**. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. *Br J Haematol* 2013;160:561-4.
DOI: 10.1111/bjh.12139
113. Virtanen JM, Itälä-Remes MA, **Remes KJ**, Vahlberg T, Saunavaara JP, Sinisalo M, Parkkola RK. Prognostic impact of pre-transplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. *Eur J Haematol* 2013;91:85-93.
DOI: 10.1111/ejh.12123
114. Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, **Remes K**, Steingrimsdottir H, Abilgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Gulbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J. Bortezomib consolidation after autologous stem cell

- transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. *Blood* 2013;121:4647-54.
DOI: 10.1182/blood-2012-11-464503
115. Ruutu T, Juvonen E, Remberger M, **Remes K**, Volin L, Mattsson J, Nihtinen A, Hägglund H, Ringden O; Nordic Group for Blood and Marrow Transplantation. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. *Biol Blood Marrow Transplant* 2014; 20:135-8.
DOI: 10.1016/j.bbmt.2013.10.014
116. Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, **Remes K**, Lundan T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K. Imatinib and pegylated IFN- α 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. *Eur J Haematol* 2014; 92: 413-20.
DOI: 10.1111/ejh.12258
117. Nylund R, Itälä-Remes M, Kauko T, Kauppila M, Putkonen M, Salmenniemi U, Salmi T, **Remes K**. Aikuisten akuutti lymfaattinen leukemia: 20 vuoden hoitotulokset TYKS:ssa. *Duodecim* 2014; 130: 714-20.
118. Silvennoinen R, Lundan T, Kairisto V, Pelliniemi T-T, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä T-L, Juvonen V, Selander T, **Remes K**. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. *Blood Cancer J* 2014;4,e250;
doi10.1038/bcj.2014.69
119. Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, **Remes K**, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; the Nordic CML Group (NCMLSG). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). *Eur J Haematol* 2015;94:243-50.
DOI: 10.1111/ejh.12423
120. Oksman MJ, Itälä-Remes M, Kauppila M, Putkonen M, Salmenniemi U, Salmi T, **Remes K**. Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma. *Bone Marrow Transplant* 2015;50:157.
DOI: 10.1038/bmt.2014.225
121. **Remes K**, Raade M, Karhumäki L, Timonen T, Välimäki MJ. v

- Iäkkään miehen hemolyysi ja levinnyt syöpä. Meilahden KPK
24.10.2013. Duodecim 2015; 131: 671-5
122. Salminen M, Kauko T, Putkonen M, Kauppila M, Salmenniemi U, Salmi T, Itälä-Remes M, **Remes K**. Uudet lääkkeet pidentävät myeloomapotilaiden elinaikaa. Suomen Lääkilehti 2015;70:
123. Salmenniemi U, Kairisto V, Leino J, Juvonen V, **Remes K**, Itälä-Remes M. Application of sensitive allele-SEQR chimerism PCR for impending relapse detection from peripheral blood in allografted AML/MDS patients treated with pre-emptive post-transplant immunomodulation. J Leuk 2015; 3: 176. doi: 10.4172/2329-6917.1000176
124. Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abilgaard N, Pedersen PT, Hammerström J, Laaksonen A, Bazia P, Terävä V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, **Remes K**. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant 2015; 50:808-12.
DOI: 10.1038/bmt.2015.39
125. Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, Kakko S, Putkonen M, Ollikainen H, Terävä V, Kutila A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Selander T, Kuittinen T, **Remes K**, Jantunen E. A randomized phase II study of stem cell mobilization with cyclophosphamide + G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant 2016;51:372-6
DOI: 10.1038/bmt.2015.236
126. Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Säily M, Sankelo M, Terävä V, Putkonen M, Kuittinen T, Pelkonen J, Mäntymaa P, **Remes K**, Varmavuo V, Jantunen E. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion 2016;56: 1394-401.
DOI: 10.1111/trf.13574
127. Varmavuo V, Silvennoinen R, Anttila P, Säily M, Sankelo M, Putkonen M, Ahonen J, Mahlamäki E, Mäntymaa P, Savolainen E-R, **Remes K**, Jantunen E. Cost-analysis of a randomized stem cell mobilization study in multiple myeloma. Ann Hematol 2016; 95:1653-9.
DOI: 10.1007/s00277-016-2772-1
128. Järvenpää J, Itälä-Remes M, Kauko T, Salmenniemi U, Kauppila M, Putkonen M, Salmi T, **Remes K**. Aikuisten akuutin myelooisen leukemian hoito. Duodecim 2016;132:1465-73.

129. Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Flöisand Y, Höglund M, **Remes K**, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. *Leukemia* 2016;
DOI: 10.1038/leu.2016.222
130. Törten J, RINGDEN o, Garming-Legert K, Ljungman P, Winarski J, **Remes K**, Itälä-Remes M, Remberger M, Mattsson J. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. *Haematologica* 2016; 101:1417-25.
DOI: 10.3324/haematol.2016.149294